Skip to main content

Cystoid Macular Edema

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
1 program
1
denufosol tetrasodiumPhase 21 trial
Active Trials
NCT00114062Terminated15Est. Dec 2006
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
denufosol tetrasodiumPhase 2
Genentech
GenentechCA - Oceanside
1 program
Ranibizumab,PHASE_11 trial
Active Trials
NCT02294656Completed4Est. Sep 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MSDdenufosol tetrasodium
GenentechRanibizumab,

Clinical Trials (2)

Total enrollment: 19 patients across 2 trials

NCT00114062MSDdenufosol tetrasodium

Study to Treat Uveitis Associated Macular Edema

Start: Sep 2005Est. completion: Dec 200615 patients
Phase 2Terminated

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

Start: Nov 2014Est. completion: Sep 20184 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.